There are 12 papers on C-terminal agrin fragment 22 in aging research: 3 trials and 8 observational studies in people, 1 review.
12 papers study it1 more mentions it16 findings
1 new paper in 30 daysSee all 13 papers on C-terminal agrin fragment 22
“Correlation analysis revealed significant correlations of plasma CAF22 with HGS, gait speed, and cumulative SPPB scores in the metformin group.”
- Human trial3
- Humans8
Interventions
7Statins
upin humans3
3 studies
Statins
upin humans3
Statins are linked with higher C-terminal agrin fragment 22 in humans.
“One year of statin usage was associated with lower HGS, gait speed, SPPB scores and higher SAMS scores and plasma CAF22 levels (all P < .05).”
Humans1 yearmalesn = 76
British journal of clinical pharmacology
Statins are linked with higher C-terminal agrin fragment 22 in humans (patients with CHF taking statin versus nonstatin group).
“Further investigations revealed a significant induction of CAF22, zonulin, and CRP in patients with CHF taking statin versus nonstatin group.”
Humanspatients with CHF taking statin versus nonstatin group
Journal of cardiovascular pharmacology
Statins are linked with higher C-terminal agrin fragment 22 in COPD patients (p < 0.05).
“Statins further reduced HGS and elevated CAF22 in COPD patients (both p < 0.05).”
Humansin COPD patientsplasmaone yearmales
Respiratory medicine
Whey protein + vitamin D
downin humans1
1 study
Whey protein + vitamin D
downin humans1
Whey protein + vitamin D decreases C-terminal agrin fragment 22 in patients with chronic obstructive pulmonary disease (p <0.05).
“Whey-D also reduced plasma CAF22 levels (p <0.05), suggesting NMJ repair, but did not alter plasma NfL.”
Human trialin patients with chronic obstructive pulmonary diseaseplasma16 weeksn = 80
Archives of medical research
Semaglutide
upin humans1
1 study
Semaglutide
upin humans1
Semaglutide increases C-terminal agrin fragment 22 in humans (compared with sitagliptin control group) (more pronounced elevation than sitagliptin group).
“this group exhibited more pronounced elevation of plasma CAF22 and NfL levels compared to the sitagliptin group (all P < .05)”
Human trialcompared with sitagliptin control group1 yearmalesn = 68
British journal of clinical pharmacology
Statin withdrawal
downin humans1
1 study
Statin withdrawal
downin humans1
Statin withdrawal is linked with lower C-terminal agrin fragment 22 in humans.
“Conversely, 6 months after statin withdrawal, gait speed and SPPB scores were restored with a concurrent reduction in SAMS and CAF22 levels (all P < .05).”
Humans6 monthsmalesn = 76
British journal of clinical pharmacology
Angiotensin-converting enzyme inhibitors
downin humans1
1 study
Angiotensin-converting enzyme inhibitors
downin humans1
Angiotensin-converting enzyme inhibitors are linked with lower C-terminal agrin fragment 22 in humans (congestive heart failure) (P < .0001).
“The level of CAF22 was significantly lower (P < .0001) in the ACEi-treated compared to non-ACEi CHF patients.”
Humanscongestive heart failureplasma
British journal of clinical pharmacology
Metformin
downin humans1
1 study
Metformin
downin humans1
Metformin decreases C-terminal agrin fragment 22 in humans (compared with baseline).
“Metformin also reduced plasma CAF22 and NfL levels when compared to baseline.”
Human trialcompared with baseline1700 mg twice a day16 weeksmales
Archives of gerontology and geriatrics
Butyrate
downin humans1
1 study
Butyrate
downin humans1
Butyrate decreases C-terminal agrin fragment 22 in humans (COPD patients) (all p < 0.05).
“Butyrate also reduced the plasma levels of zonulin, LBP, and CAF22 levels in COPD patients (all p < 0.05).”
Human trialCOPD patientscapsuleplasma300 mg capsule a day12 weeksn = 64
Respiratory medicine
Associations
4Handgrip strength
downin humans3
3 studies
Handgrip strength
downin humans3
C-terminal agrin fragment 22 is associated with handgrip strength in humans (treatment-related changes in MIBC patients) (r = -0.80).
“CAF22 changes correlated with HGS (r = - 0.80) and SPPB (r = - 0.75), while NfL showed weaker but significant correlations.”
Humanstreatment-related changes in MIBC patientsplasman = 42
International journal of clinical oncology
C-terminal agrin fragment 22 predicts handgrip strength in humans (at baseline (T1) in MIBC patients) (β = -0.58, p < 0.001).
“CAF22 was significantly associated with lower HGS and SPPB at T1 (β = - 0.58 and - 0.42, p < 0.001).”
Humansat baseline (T1) in MIBC patientsplasman = 42
International journal of clinical oncology
C-terminal agrin fragment 22 is associated with handgrip strength in humans (patients with CHF) (r2 = 0.34, P < 0.0001).
“There were strong inverse correlations of CAF22 with HGS (r 2 = 0.34, P < 0.0001), short physical performance battery scores (r 2 = 0.08, P = 0.0001), and GS (r 2 = 0.143, P < 0.0001).”
Humanspatients with CHF
Journal of cardiovascular pharmacology
C-terminal agrin fragment 22 is associated with handgrip strength in patients with AD and controls (p < 0.05).
“Plasma zonulin and CAF22 exhibited robust negative associations with HGS and relatively weak but statistically significant associations with gait speed and ASMI (all p < 0.05).”
Humansin patients with AD and controls
Neuroscience research
Muscle-invasive bladder cancer
upin humans1
1 study
Muscle-invasive bladder cancer
upin humans1
Muscle-invasive bladder cancer is associated with C-terminal agrin fragment 22 in humans (before and after neoadjuvant chemotherapy and post-radical cystectomy).
“Plasma CAF22 and NfL were significantly elevated in patients versus controls at all time points.”
Humansbefore and after neoadjuvant chemotherapy and post-radical cystectomyplasma
International journal of clinical oncology
Congestive heart failure
upin humans1
1 study
Congestive heart failure
upin humans1
C-terminal agrin fragment 22 predicts congestive heart failure in humans (congestive heart failure) (95% CI: 0.785-0.883; P < .0001).
“The receiver operating characteristic curve analysis revealed CAF22 as a potential diagnostic marker (95% confidence interval: 0.785-0.883; P < .0001) for CHF.”
Humanscongestive heart failure
British journal of clinical pharmacology
Cumulative short physical performance battery score
mixedin humans1
1 study
Cumulative short physical performance battery score
mixedin humans1
C-terminal agrin fragment 22 is associated with cumulative short physical performance battery score in the metformin group.
“Correlation analysis revealed significant correlations of plasma CAF22 with HGS, gait speed, and cumulative SPPB scores in the metformin group.”
Human trialin the metformin group1700 mg twice a day16 weeksmales
Archives of gerontology and geriatrics